06 · THE CHART · Who we treat · PE-backed platform

Admen · GROWTH PARTNERS FOR HEALTHCARE OPERATORS
BY APPLICATION · ~6 / QUARTER DIAGNOSTIC PROFILE · P-01

PT / Who we treat / P-01 · PE-BACKED PLATFORM

Buyers don't pay for growth. They pay for growth they can re-run.

14 engagements. Platforms present with EBITDA bought and growth rented — every acquisition brings another website, another agency, another CRM. Multiple expansion is a marketing problem long before it's a finance one.

S

SUBJECTIVE

"Same-store growth stalls after integration." · "We're running six marketing stacks and can't compare any of them." · "Our growth story is a slide, not a system."

O

OBJECTIVE — typical intake

Post-close organic growth decaying by acquisition cohort · 6—20 marketing stacks across the platform · CAC unmeasurable at platform level · diligence data assembled retroactively, per raise

A

ASSESSMENT

If acquisition can't be shown as a repeatable, operator-independent system, the exit multiple prices your growth as luck. Instrumented and re-runnable, it prices as a machine. That delta is the cheapest multiple expansion available.

P

PLAN

One acquisition system rolled across cohorts · platform-level CAC and payback instrumentation · banker-ready growth narrative with re-runnable data · post-close integration playbook per add-on

OUTCOMES — 14 ENGAGEMENTS · MED.

  • Multiple lift, modeled +1.5 — 2.1×
  • Marketing stacks 14 → 1
  • CAC visibility, platform 0% → 100% of locations
  • Same-store growth, organic restored by cohort
  • Months to system 9 — 14

RELATED CASE FILES